Walleye Capital’s Acrivon Therapeutics ACRV Stock Holding History

Walleye Capital’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12,721	Closed	-$73.8K	–	5195
2024 Q2	$73.8K	Buy	+12,721	New	+$102K	﹤0.01%	4828

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Capital's ACRV Position: Q3 2024 in Review

Walleye Capital sold out of Acrivon Therapeutics (ACRV) in Q3 2024, closing a stake of 12,721 shares — an estimated $73.8K sold.

Walleye Capital first reported a position in ACRV in Q2 2024 and held it in 1 quarter. The position peaked at $73.8K in Q2 2024. 55 funds tracked by Wall St. Rank hold ACRV as of Q3 2024.

Walleye Capital reported no remaining Acrivon Therapeutics position as of Q3 2024 after selling out during the quarter.
Walleye Capital sold 12,721 Acrivon Therapeutics shares in Q3 2024, an estimated $73.8K.
Walleye Capital first reported a position in Acrivon Therapeutics in Q2 2024 and held it in 1 quarter.
Walleye Capital's Acrivon Therapeutics position peaked at $73.8K in Q2 2024.
55 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.